In terms of geography, North America dominates the global major depressive disorder market due to increased awareness about various depression conditions in the region. The U.S. represents the largest market for major depressive disorder in North America, followed by Canada. In Europe, Germany, France, the U.K., Italy, and Spain account for a major share of the major depressive disorder market. This market in Asia is expected to expand at a significant rate over the next five years. This is due to various companies setting up manufacturing facilities in the region. Moreover, increasing awareness about various depression episodes and rise in geriatric population are also driving the growth of the market in the region. India, China, and Japan are expected to be the fastest growing major depressive disorder markets in Asia.
A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/4190
In recent times, increased demand for therapeutic products for the treatment of this medical condition is a key driver for the global major depressive disorder market. Increased investments in R&D in the pharmaceutical sector and introduction of innovative drugs have also fueled the growth of this market. The ongoing development of drugs with properties, such as improved safety and high patient compliance, are also supporting the growth of the global major depressive disorder market. Therapies, such as biological therapy, meditation, and physiotherapy, have immense potential to spur the growth of this market.
However, stringent regulations imposed by various governments hamper the growth of global major depressive disorder market. Moreover, the patent expiries of some blockbuster drugs (drugs that have an annual sale of USD 1.0 million and above) and risk of complications and side-effects associated with antidepressants have hindered the growth of the market. Increasing mergers and acquisitions of drug manufacturing companies and rapid product launches are some of the major trends in the global major depressive disorder market.
To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/4190
The major companies operating in this market are H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., AstraZeneca Plc, Alkermes, Takeda Pharmaceutical Company Limited, Naurex, Euthymics Bioscience, Inc., e-Therapeutics plc, Eli Lilly and Company, and Pfizer Inc.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353